Cover Image
市場調查報告書

Nymox Pharmaceutical Corporation - 產品平台分析

Nymox Pharmaceutical Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224625
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Nymox Pharmaceutical Corporation - 產品平台分析 Nymox Pharmaceutical Corporation - Product Pipeline Review - 2015
出版日期: 2015年07月31日 內容資訊: 英文 39 Pages
簡介

Nymox Pharmaceutical Corporation 是以針對高齡者未滿足需求為目標,研發治療藥及診斷裝置的生物製藥公司。

本報告提供Nymox Pharmaceutical Corporation的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Nymox Pharmaceutical Corporation的基本資料

Nymox Pharmaceutical Corporation概要

  • 主要資訊
  • 企業資料

Nymox Pharmaceutical Corporation:R&D概要

  • 主要的治療範圍

Nymox Pharmaceutical Corporation:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Nymox Pharmaceutical Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Nymox Pharmaceutical Corporation:藥物簡介

  • NX-1207
  • Drugs for Oncology
  • NXB-4221
  • NXD-1191
  • NXD-3109
  • NXD-5150
  • NXD-9062
  • NXB-5886
  • NXC-4720
  • NXT-1021

Nymox Pharmaceutical Corporation:開發平台分析

  • 各給藥途徑
  • 各分子類型

Nymox Pharmaceutical Corporation:最近的開發平台趨勢

Nymox Pharmaceutical Corporation:暫停中的計劃

Nymox Pharmaceutical Corporation:企業發表

Nymox Pharmaceutical Corporation:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07200CDB

Summary

Global Markets Direct's, 'Nymox Pharmaceutical Corporation - Product Pipeline Review - 2015', provides an overview of the Nymox Pharmaceutical Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nymox Pharmaceutical Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Nymox Pharmaceutical Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Nymox Pharmaceutical Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Nymox Pharmaceutical Corporation's pipeline products

Reasons to buy

  • Evaluate Nymox Pharmaceutical Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Nymox Pharmaceutical Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Nymox Pharmaceutical Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Nymox Pharmaceutical Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nymox Pharmaceutical Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Nymox Pharmaceutical Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Nymox Pharmaceutical Corporation Snapshot
    • Nymox Pharmaceutical Corporation Overview
    • Key Information
    • Key Facts
  • Nymox Pharmaceutical Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Nymox Pharmaceutical Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Nymox Pharmaceutical Corporation - Pipeline Products Glance
    • Nymox Pharmaceutical Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Nymox Pharmaceutical Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Nymox Pharmaceutical Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Nymox Pharmaceutical Corporation - Drug Profiles
    • NX-1207
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NXB-4221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NXC-4720
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NXB-5886
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NXT-1021
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nymox Pharmaceutical Corporation - Pipeline Analysis
    • Nymox Pharmaceutical Corporation - Pipeline Products by Route of Administration
    • Nymox Pharmaceutical Corporation - Pipeline Products by Molecule Type
  • Nymox Pharmaceutical Corporation - Recent Pipeline Updates
  • Nymox Pharmaceutical Corporation - Dormant Projects
  • Nymox Pharmaceutical Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • NX-1207
  • Nymox Pharmaceutical Corporation - Company Statement
  • Nymox Pharmaceutical Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Nymox Pharmaceutical Corporation, Key Information
  • Nymox Pharmaceutical Corporation, Key Facts
  • Nymox Pharmaceutical Corporation - Pipeline by Indication, 2015
  • Nymox Pharmaceutical Corporation - Pipeline by Stage of Development, 2015
  • Nymox Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2015
  • Nymox Pharmaceutical Corporation - Phase III, 2015
  • Nymox Pharmaceutical Corporation - Phase II, 2015
  • Nymox Pharmaceutical Corporation - Preclinical, 2015
  • Nymox Pharmaceutical Corporation - Discovery, 2015
  • Nymox Pharmaceutical Corporation - Pipeline by Route of Administration, 2015
  • Nymox Pharmaceutical Corporation - Pipeline by Molecule Type, 2015
  • Nymox Pharmaceutical Corporation - Recent Pipeline Updates, 2015
  • Nymox Pharmaceutical Corporation - Dormant Developmental Projects,2015
  • Nymox Pharmaceutical Corporation - Discontinued Pipeline Products, 2015
  • Nymox Pharmaceutical Corporation, Subsidiaries

List of Figures

  • Nymox Pharmaceutical Corporation - Pipeline by Top 10 Indication, 2015
  • Nymox Pharmaceutical Corporation - Pipeline by Stage of Development, 2015
  • Nymox Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2015
  • Nymox Pharmaceutical Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Nymox Pharmaceutical Corporation - Pipeline by Top 10 Molecule Type, 2015
Back to Top